Is there a role for antioxidants in the prevention of infection-associated carcinogenesis and in the treatment of infection-driven tumors?

Current Topics in Medicinal Chemistry

Volumn 15, Issue 2, 2015, Pages 120-135

  De Luca, Chiara ^a   Kharaeva, Zaira ^b   Korkina, Liudmila ^a  

^a Centre of Innovative Biotechnological Investigations Nanolab   (Russian Federation)

^b KABARDINO BALKARIAN STATE UNIVERSITY   (Russian Federation)

Author keywords

Antioxidants; Cervical cancer; Chemoprevention; Gastric adenocarcinoma; Hepatocarcinoma; Redox active compounds; TRAIL; Viruses

Indexed keywords

ALOE VERA EXTRACT; ANTIOXIDANT; BETA CAROTENE; EMBLICA OFFICINALIS EXTRACT; GREEN TEA EXTRACT; HERBACEOUS AGENT; MICRORNA; PHENOL DERIVATIVE; PLANT EXTRACT; POLYPHENOL; PRANEEM; REACTIVE OXYGEN METABOLITE; RESVERATROL; SAPINDUS MUKOROSSI EXTRACT; TRACE ELEMENT; UNCLASSIFIED DRUG; VIRUS PROTEIN; VITAMIN;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); HELICOBACTER PYLORI; HEPATITIS B VIRUS; HOST PARASITE INTERACTION; HUMAN; INFECTION; LIVER CELL CARCINOMA; NEOPLASM; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIZATION; STOMACH CANCER; TUMOR GROWTH; UTERINE CERVIX CANCER; VIRUS INFECTION; VITAMIN SUPPLEMENTATION; WART VIRUS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; FEMALE; LIVER NEOPLASMS; PAPILLOMAVIRIDAE; STOMACH NEOPLASMS; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ANTIOXIDANTS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; FEMALE; HELICOBACTER PYLORI; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; PAPILLOMAVIRIDAE; STOMACH NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84926358422     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666141209145022     Document Type: Article

References (172)

1. [1][1] De Martel, C.; Ferlay, J.; Franceschi, S.; Vignat, J.; Bray, F.; Forman, D.; Plummer, M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol., 2012, 13(6), 607-615.
2. [2][2] Kutikhin, A.G.; Yuzhalin, A.E.; Brusina, E.B.; Briko, N.I. Role of infectious agents in the emergence of malignant tumors. Zh. Mikrobiol. Epidemiol. Immunobiol., 2012, 5, 104-114.
3. [3][3] Mandong, B.M.; Ngbea, J.A.; Vhriterhire, R. Role of parasites in cancer. Nigerian J. Med., 2013, 22(2), 89-92.
4. [4][4] Ohnishi, S.; Ma, N.; Thanan, R.; Pinlaor, S. Hammam, O.; Murata, M.; Kawanishi, S.; Kawanishi, S. DNA Damage in Inflammation-Related Carcinogenesis and Cancer Stem Cells. Oxid. Med. Cell Longev., 2013, 2013, 387014. doi: 10.1155/2013/387014.
5. [5][5] Akaike, T.; Fujii, S.; Kato, A.; Yoshitake, J.; Miyamoto, Y.; Sawa, T.; Okamoto, S.; Suga, M.; Asakawa, M.; Nagai, Y.; Maeda, H. Viral mutation accelerated by nitric oxide production during infection in vivo. FASEB J., 2000, 14(10), 1447-1454.
6. Beck, M.A. Antioxidants and viral infections: host immune response and viral pathogenicity. J Am. Coll. Nutr., 2001, 20(5 Suppl), 384S-388S, discussion 396S-397S.
7. [7][7] Sinkovics, J.G. Molecular biology of oncogenic inflammatory processes. I. Non-oncogenic and oncogenic pathogens, intrinsic inflammatory reactions without pathogens, and microRNA/DNA interactions. Int. J. Oncol., 2012,40(2), 305-349.
8. [8][8] Huang, J.; Plass, C.; Gerhauser, C. Cancer chemoprevention by targeting the epigenome. Curr. Drug Targets, 2011, 12(13), 1925-1956.
9. [9][9] De Marco, E.; Bucaj, E.; Foppoli, C.; Fiorini, A.; Blarzino, C.; Filipi, K.; Giorgi, A.; Schinina, M.E.; Di Domenico, F.; Coccia, R.; Butterfield, D.A.; Perluigi, M. Oxidative stress in HPV-driven viral carcinogenesis: redox proteomics analysis of HPV-16 dysplastic and neoplastic tissues. PLoS One, 2012, 7(3), e34366. doi: 10.1371/journal.pone.0034366.
10. Wei, L.; Gravitt, P.E.; Song, H.; Maldonado, A.M.; Ozbun, M.A. Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human Papillomavirusinfected cells. Cancer Res., 2009, 69(11), 4878-4884.
11. Gorrini, C.; Harris, I.S.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov., 2013, 12(12), 931-947.
12. Deramaudt, T.B.; Dill, C.; Bonay, M. Regulation of oxidative stress by Nrf2 in the pathophysiology of infectious diseases. Med. Mal. Infect., 2013, 43(3), 100-107.
13. Abel, S.; De Kock, M.; van Schalkwyk, D.J.; Swanevelder, S.; Kew, M.C.; Gelderblom, W.C.A. Altered lipid profile, oxidative status and hepatitis B virus interactions in human hepatocellular carcinoma. Prostaglandins Leukot. Essent. Fatty Acids, 2009, 81(5-6), 391-399.
14. Akaike, T. Role of free radicals in viral pathogenesis and mutation. Rev. Med. Virol., 2001, 11(2), 87-101.
15. Georgakilas, A.G.; Mosley, W.G.; Georgakila, S.; Ziech, D.; Panayiotidis, M.I. Viral-induced human carcinogenesis: an oxidative stress perspective. Mol. Biosyst., 2010, 6(7):1162-1172.
16. Halazonetis, T.D.; Gorgoulis, V.G.; Bartek, J. An oncogeneinduced DNA damage model for cancer development. Science, 2008, 319(5868), 1352-1355.
17. Bartsch, H.; Jagadeesan, N. Oxidative stress and lipid peroxidationderived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect. Prevent., 2004, 28(6), 385-391.
18. Katayama, Y.; Takahashi, M.; Kuwayama, H. Helicobacter pylori causes runx3 gene methylation and its loss of expression in gastric epithelial cells, which is mediated by nitric oxide produced by macrophages. Biochem. Biophys. Res. Commun., 2009, 388(3), 496-500.
19. Holland, B.; Wong, J.; Li, M.; Rasheed, S. Identification of human microRNA-like sequences embedded within the protein-encoding genes of the human immunodeficiency virus. PLoS One, 2013, 8(3), e58586. doi: 10.1371/journal.pone.0058586.
20. Lo, A.K.; Dawson, C.W.; Jin, D.J.; Lo, K.W. The pathological roles of BART miRNAs in nasofaringeal carcinoma, J. Pathol., 2012, 227(4), 392-403.
21. Nambaru, L.; Meenakamuri, B.; Swaminathan, R.; Raikumar, T. Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pac. J. Cancer Prev., 2009, 10(3), 355-360.
22. Toth, Z.; Brulois, K.; Jung, J.U. The chromatin landscape of Kaposi’s sarcoma associated herpesvirus. Viruses, 2013, 5(5), 1346-1373.
23. Wang, Z.; Ly, Y.; Ahmad, A.; Azmi, A.S.; Kong, D.; Banerjee, S.; Sarkar, F.H. Targeting microRNAs involved in cancer stem cells and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist. Updat., 2010, 13(4-5), 109-118.
24. Maitland, N.J.; Collins, A.T. Inflammation as the primary aetiological agent of human prostate cancer: a stem cell connection. J. Cell. Biochem., 2008, 105(40), 931-939.
25. Li, Y.; Kong, D.; Wang, Z.; Sarkar, F.H. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res., 2010, 27(6),1027-1041.
26. Tew, K.D. NrF2⁄Keap1 as gatekeepers of redox homeostasis-do they prevent or cause cancer? Pigment Cell Melanoma Res., 2011, 24(6), 1078-1079.
27. DeNicola, G.M.; Karreth, F.A.; Humpton, T.J.; Gopinathan, A.; Wei, C.; Frese, K.; Mangal, D.; Yu, K.H.; Yeo, C.J.; Calhoun, E.S.; Scrimieri, F.; Winter, J.M.; Hruban, R.H.; Iacobuzio-Donahue, C.; Kern, S.E.; Blair, I.A.; Tuveson, D.A. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 2011, 475(7354), 106-109.
28. Perera, R.M.; Bardeesy, N. Cancer: when antioxidants are bad. Nature, 2011, 475(7354), 43-44.
29. Deghan Manshadi, S.; Ishiguro, L.; Sohn, K.J.; Medline, A.; Renlund, R.; Croxford, R.; Kim, Y.I. Folic acid supplementation promotes mammary tumor progression in a rat model. PLoS One, 2014, 9(1):e84635. doi: 10.1371/journal.pone.0084635.
30. Aragon, F.; Perdigon, G.; deMoreno de LeBlanc, A. Modification in the diet can induce beneficial effects against breast cancer. World J. Clin. Oncol., 2014, 5(3), 455-464.
31. Hsieh, C.L.; Peng, C.C.; Cheng, Y.M.; Lin, L.Y.; Ker, Y.B.; Chang, C.H.; Chen, K.C.; Peng, R.Y. Quercetin and ferulic acid aggravate renal carcinoma in long-term diabetic victims. J. Agric. Food Chem., 2010, 58(16), 9273-9280.
32. Tandon, R.; Khanna, H.D.; Dorababu, M.; Goel, R.K. Oxidative stress and antioxidants status in peptic ulcer and gastric carcinoma. Indian J. Physiol. Pharmacol., 2004, 48(1), 115-118.
33. Liu, Q.Y.; Tan, B.K. Dietary fish oil and vitamin E enhance doxorubicin effects in P388 tumor-bearing mice. Lipids, 2002, 37(6), 549-556.
34. Wang, Z.; Ly, Y.; Ahmad, A.; Azmi, A.S.; Kong, D.; Banerjee, S.; Sarkar, F.H. Targeting microRNAs involved in cancer stem cells and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist. Updat., 2010, 13(4-5), 109-118.
35. Gerhauser, C. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Top Curr. Chem., 2013, 329, 73-132.
36. Korkina, L.; De Luca, C., Kostyuk, V.; Pastore, S. Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments. Curr. Med. Chem., 2009, 16(30), 3943-3965.
37. Schaffer, M.; Schaffer, P.M.; Zidan, J.; Bar Sela, G. Curcuma as a functional food in the control of cancer and inflammation. Curr. Opin. Clin. Nutr. Metab. Care, 2011, 14(6), 588-597.
38. Korkina, L.; De Luca, C.; Pastore, S. Plant polyphenols and human skin: friends or foes. Ann. N. Y. Acad. Sci., 2012, 1259, 77-86.
39. Firuzi, O.; Miril, R.; Tavakkoli, M.; Saso L. Antioxidant Therapy: Current Status and Future Prospects. Curr. Med. Chem., 2011, 18(25), 3871-3888.
40. Kostyuk, V.; Potapovich, A.; De Luca, C. The Promise of Plant Polyphenols as the Golden Standard Skin Anti-Inflammatory Agents. Curr. Drug Metab., 2010, 11(5), 414-424.
41. Gao, W.; Chan, J.Y.; Wong, T.S. Curcumin exerts inhibitory effects on undifferentiated nasopharyngeal carcinoma by inhibiting the expression of miR-125-5p. Clin. Sci., (Lond), 2014, 127(9), 571-579.
42. Li, Y.; Zhang, T. Targeting stem cells by curcumin and clinical applications. Cancer Lett., 2014, 346 (2), 197-205.
43. Khanna, N.; Dalby, R.; Tan, M.; Arnold, S.; Stern, J.; Frazer, N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol. Oncol., 2007, 107(3), 554-562.
44. Tommasino, M. The human papillomavirus family and its role in carcinogenesis. Semin. Cancer Biol., 2014, 26, 13-21.
45. Wallin, K.L.; Wiklund, F.; Angstrom, T.; Bergman, F.; Stendahl, U.; Wadell, G.; Hallmans, G.; Dillner, J. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Engl. J. Med., 1999, 341(22), 1633-1638.
46. Tornesello, M.L.; Buonaguro, L.; Giorgi-Rossi, P.; Buonaguro, F.M. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed. Res. Int., 2013, 2013, 519619. doi: 10.1155/2013/519619.
47. Carlos de Freitas, A.; Campos Coimbra, E.; daConceicao Gomes Leitao, M. Molecular targets of HPV oncoproteins: Potential biomarkers for cervical carcinogenesis. Biochim. Biophys. Acta, 2014, 1845(2), 91-103.
48. Longworth, M.S.; Laimins, L.A. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol. Mol. Biol. Rev., 2004, 68(2), 362-372.
49. Hiraku, Y.; Tabata, T.; Ma, N.; Murata, M.; Ding, X.; Kawanishi, S. Nitrative and oxidative DNA damage in cervical intraepithelial neoplasia associated with human papilloma virus infection. Cancer Sci., 2007, 98(7), 964-972.
50. Rahkola, P.; Vaaisanen-Tommiska, M.; Tuomikoski, P.; Ylikorkala, O.; Mikkola, T.S. Cervical nitric oxide release and persistence of high-risk human papillomavirus in women. Int. J. Cancer, 2011, 128(12), 2933-2937.
51. Rahkola-Soisalo, P.; Mikkola, T.S.; Vuorento, S.; Ylikorkala, O.; Vaaisanen-Tommiska, M., Smoking is accompanied by a suppressed cervical nitric oxide release in women with high-risk human papillomavirus infection. Acta. Obstet. Gynecol. Scand., 2013, 92(6), 711-715.
52. Zhen, S.; Hu, C.M.; Bian, L.H. Glutathione S-transferase polymorphism interactions with smoking status and HPV infection in cervical cancer risk: an evidence-based meta-analysis. PLoS One, 2013, 8(12):e83497. doi: 10.1371/journal.pone.0083497.
53. Crescencio, M.E.; Rodriguez, E.; Paez, A.; Masso, F.A.; Montano, L.F.; Lopez-Marure, R. Statins inhibit the proliferation and induce cell death of human papilloma virus positive and negative cervical cancer cells. Int. J. Biomed. Sci., 2009, 5(4), 411-420.
54. Carrero, Y.; Callejas, D.; Alana, F.; Silva, C.; Mindiola, R.; Mosquera, J. Increased vascular endothelial growth factor expression, CD3-positive cell infiltration, and oxidative stress in premalignant lesions of the cervix. Cancer, 2009, 115(16), 3680-3680.
55. Kipanyula, M.J.; Seke Stet, P.F.; Vecchio, L.; Farahna, M.; Nukenine, E.N.; Nwabo Kamdje, A.H. Signaling pathways bridging microbial-triggered inflammation and cancer. Cell Signal., 2013, 25(2), 403-416.
56. Ha, H.-L.; Shin, H.-J.; Feitelson, M.A.; Yu, D.J. Oxidative stress and antioxidants in hepatic pathogenesis. World J. Gastroenterol., 2010, 16(48), 6035-6043.
57. Yamashita, T.; Honda, M.; Takatori, H.; Nishino, R.; Minato, H.; Takamura, H.; Ohta, T.; Kaneko, S. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J. Hepatic., 2009, 50(1), 100-110.
58. Petersen, J.; Dandri, M.; Burkle, A.; Zhang, L.; Rogler, C.E. Increase in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair. J. Virol., 1997, 71(7), 5455-5463.
59. Shimoda, R.; Nagashima, M.; Sakamoto, M.; Yamaguchi, N.; Hirohashi, S.; Yokota, J.; Kasai, H. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res., 1994, 54(12), 3171-3172.
60. Hui-Ching Wang, H.-C.; Huang, W.; Lai, M.-D., Su, I.-J. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci., 2006, 97(8), 683-688.
61. Abel, S.; Smuts, C.M.; de Villiers, C.; Gelderblom, W.C. Changes in essential fatty acid patterns associated with normal liver regeneration and the progression of hepatocyte nodules in rat hepatocarcinogenesis. Carcinogenesis, 2001, 22(5), 795-804.
62. Bartsch, H.; Jagadeesan, N. Accumulation of lipid peroxidationderived DNA lesions: Potential lead markers for chemoprevention of inflammation-driven malignancies. Mutation Res., 2005, 591, 34-44.
63. Ma, Y.; Zhang, L.; Rong, S.; Qu, H.; Zhang, Y.; Chang, D.; Hongzhi Pan, H.; Wang, W. Relation between gastric cancer and protein oxidation, DNA damage, and lipid peroxidation. Oxid. Med. Cell Longev., 2013, 543760. doi: 10.1155/2013/543760.
64. Sipowicz, M.A.; Chomarat, P.; Diwan, B.A.; Anver, M.A.; Awasthi, Y.C.; Ward, J.M.; Rice, J.M.; Kasprzak, K.S.; Wild, C.P.; Anderson, L.M. Increased oxidative DNA damage and hepatocyte overexpression of specific cytochrome P450 isoforms in hepatitis of mice infected with helicobacter hepaticus. Am. J. Pathol., 1997, 151(4), 933-941.
65. Suzuki, H.; Nishizawa, T.; Tsugawa, H.; Mogami, S.; Hibi, T. Roles of oxidative stress in stomach disorders. J. Clin. Biochem. Nutr., 2012, 50(1), 35-39.
66. Bereswill, S.; Neuner, O.; Strobel, S.; Kist, M. Identification and molecular analysis of superoxide dismutase isoforms in Helicobacter pylori. FEMS Microbiol. Lett., 2000, 183(2), 241-245.
67. Bauer, G.; Bereswill, S.; Aichele, P.; Glocker, E. Helicobacter pylori protects oncogenically transformed cells from reactive oxygen species-mediated intercellular induction of apoptosis Carcinogenesis, 2014, 35(7), 1582-1591.
68. Morishita, K.; Takeuchi, H.; Morimoto, N.; Shimamura, T.; Kadota, Y.; Tsuda, M.; Taniguchi, T,.; Ukeda, H.; Yamamoto, T.; Sugiura, T. Superoxide dismutase activity of Helicobacter pylori per se from 158 clinical isolates and the characteristics. Microbiol. Immunol., 2012, 56(4), 262-72.
69. Shi, Y.Y.; Chen, M.; Zhang, Y.X.; Zhang, J.; Ding, S.G. Expression of three essential antioxidants of Helicobacter pylori in clinical isolates. J. Zhejiang Univ. Sci. B., 2014, 15(5), 500-506.
70. Hye Yeon Baek, H.Y.; Lim, J.W.; Kim, H.; Kim, J.M.; Kim, J.S.; Jung, H.C.; Kim, K.H. Oxidative-stress-related proteome changes in Helicobacter pylori-infected human gastric mucosa. Biochem. J., 2004, 379(Pt.2), 291-299.
71. Handa, O.; Naito, Y.; Yoshikawa, T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep., 2011, 16(1), 1-7.
72. Steenport, M.; Eom, H.; Uezu, M.; Schneller, J.; Gupta, R.; Mustafa, Y.; Villanueva, R.; Straus, E.W.; Raffaniello, R.D. Association of polymorphisms in myeloperoxidase and catalase genes with precancerous changes in the gastric mucosa of patients at inner-city hospitals in New York. Oncol. Rep., 2007, 18(1), 235-240.
73. Noyan, T.; Guducuoglu, H.; Ilhan, M. A study of oxidative stress parameters in anti-Helicobacter pylorus immunoglobulin G positive and negative gastric cancer patients. Yonsei Med. J., 2009, 50(5), 677-682.
74. Ock, C.Y.; Kim, E.H.; Choi, D.J.; Lee, H.J.; Hahm, K.B.; Chung, M.H. 8-hydroxydeoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated gastrointestinal diseases. World J. Gastroenterol., 2012, 18(4), 302-308.
75. Korkina, L.G.; Pastore, S.; Dellambra, E.; De Luca, C. New molecular and cellular targets for chemoprevention and treatment of skin tumors by plant polyphenols: a critical review. Curr. Med. Chem., 2013, 20(7), 852-868.
76. Kwasoniewska, A.; Tukendorf, A.; Semczuk, M. Frequency of HPV infection and the level of ascorbic acid in serum of women with cervix dysplasia. Med. Dosw. Mikrobiol., 1996, 48(3-4), 183-188.
77. Ekstrom, A.M.; Serafini, M.; Nyren, O.; Hansson, L.E.; Ye, W.; Wolk, A. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int. J. Cancer, 2000, 87(1), 133-140.
78. Jarosz, M.; Dzieniszewski, J.; Dabrowska-Ufniarz, E.; Wartanowicz, M.; Ziemlanski, S. Tobacco smoking and vitamin C concentration in gastric juice in healthy subjects and patients with Helicobacter pylori infection. Eur. J. Cancer Prev., 2000 , 9(6), 423-428.
79. Persson, C.; Sasazuki, S.; Inoue, M.; Kurahashi, N.; Iwasaki, M.; Miura, T.; Ye, W.; Tsugane, S. Plasma levels of carotenoids, retinol and tocopherol and the risk of gastric cancer in Japan: a nested case-control study. Carcinogenesis, 2008, 29(5), 1042-1048.
80. Jenab, M.; Riboli, E.; Ferrari, P.; Friesen, M.; Sabate, J.; Norat, T.; Slimani, N.; Tjunneland, A.; Olsen, A.; Overvad, K.; Boutron-Ruault, M.C.; Clavel-Chapelon, F.; Boeing, H.; Schulz, M.; Linseisen, J.; Nagel, G.; Trichopoulou, A.; Naska, A.; Oikonomou, E.; Berrino, F.; Panico, S.; Palli, D.; Sacerdote, C.; Tumino, R.; Peeters, P.H.; Numans, M.E.; Bueno-de-Mesquita, H.B.; Bochner, F.L.; Lund, E.; Pera, G.; Chirlaque, M.D.; Sanchez, M.J.; Arriola, L.; Barricarte, A.; Quiros, J.R.; Johansson, I.; Johansson, A.; Berglund, G.; Bingham, S.; Khaw, K.T.; Allen, N.; Key, T.; Carneiro, F.; Save, V.; Del Giudice, G.; Plebani, M.; Kaaks, R.; Gonzalez, C.A. Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition. Br. J. Cancer, 2006, 95(3), 406-415.
81. Webb, P.M.; Bates, C.J.; Palli, D.; Forman, D. Gastric cancer, gastritis and plasma vitamin C: results from an international correlation and cross-sectional study. The Eurogast Study Group. Int. J. Cancer, 1997, 73(5), 684-689.
82. Ma, J.L.; Zhang, L.; Brown, L.M.; Li, J.Y.; Shen, L.; Pan, K.F.; Liu, W.D.; Hu, Y.; Han, Z.X.; Crystal-Mansour, S.; Pee, D.; Blot, W.J.; Fraumeni, J.F.; You, W.C.; Gail, M.H. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J. Natl. Cancer Inst., 2012, 104(6), 488-492.
83. Plummer, M.; Vivas, J.; Lopez, G.; Bravo, J.C.; Peraza, S.; Carillo, E.; Cano, E.; Castro, D.; Andrade, O.; Sanchez, V.; Garcia, R.; Buiatti, E.; Aebischer, C.; Franceschi, S.; Oliver, W.; Munoz, N. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J. Natl. Cancer Inst., 2007, 99(2), 137-146.
84. You, W.C.; Brown, L.M.; Zhang, L.; Li, J.Y.; Jin, M.L.; Chang, Y.S.; Ma, J.L.; Pan, K.F.; Liu, W.D. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J. Natl. Cancer Inst., 2006, 98(14), 974-983.
85. Jarosz, M.; Dzieniszewski, J.; Dabrowska-Ufniarz, E.; Wartanowicz, M.; Ziemlanski, S.; Reed, P.I. Effects of high dose vitamin C treatment on Helicobacter pylori infection and total vitamin C concentration in gastric juice. Eur. J. Cancer Prev., 1998, 7(6), 449-454.
86. Gail, M.H.; You, W.C.; Chang, Y.S.; Zhang, L.; Blot, W.J.; Brown, L.M.; Groves, F.D.; Heinrich, J.P.; Hu, J.; Jin, M.L.; Li, J.Y.; Liu, W.D.; Ma, J.L.; Mark, S.D.; Rabkin, C.S.; Fraumeni, J.F.; Xu, G.W. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin. Trials., 1998, 19(4), 352-369.
87. Ahn, W.S.; Yoo, J.; Huh, S.W.; Kim, C.K.; Lee, J.M.; Namkoong, S.E.; Bae, S.M.; Lee, I.P. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Cancer Prev., 2003, 12(5), 383-390.
88. De Luca, C.; Kharaeva, Z.; Raskovic, D.; Pastore, P.; Luci, A.; Korkina, L. Coenzyme Q10, vitamin E, selenium, and methionine in the treatment of chronic recurrent viral mucocutaneous infections. Nutrition, 2008, 28(5), 509-514.
89. Dreno, B.; Euvrard, S.; Frances, C.; Moyse, D.; Nandeuil, A. Effect of selenium intake on the prevention of cutaneous epithelial lesions in organ transplant recipients. Eur. J. Dermatol., 2007, 17(2), 140-145.
90. Keefe, K.A.; Schell, M.J.; Brewer, C.; McHale, M.; Brewster, W.; Chapman, J.A.; Rose, G.S.; McMeeken, D.S.; Lagerberg, W.; Peng, Y.M.; Wilczynski, S.P.; Anton-Culver, H.; Meyskens, F.L.; Berman, M.L. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev., 2001, 10(10), 1029-1035.
91. Varis, K.; Taylor, P.R.; Sipponen, P.; Samloff, I.M.; Heinonen, O.P.; Albanes, D.; Harkonen, M.; Huttunen, J.K.; Laxen, F.; Virtamo, J. Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alphatocopherol and beta-carotene. The Helsinki Gastritis Study Group. Scand. J. Gastroenterol., 1998, 33(3), 294-300.
92. Correa, P.; Fontham, E.T.; Bravo, J.C.; Bravo, L.E.; Ruiz, B.; Zarama, G.; Realpe, J.L.; Malcom, G.T.; Li, D.; Johnson, W.D.; Mera, R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J. Natl. Cancer Inst., 2000, 92(23), 1881-1888.
93. Sasazuki, S.; Sasaki, S.; Tsubono, Y.; Okubo, S.; Hayashi, M.; Kakizoe, T.; Tsugane, S. The effect of 5-year vitamin C supplementation on serum pepsinogen level and Helicobacter pylori infection. Cancer Sci., 2003, 94(4), 378-382.
94. Berspalov, V.G.; Shcherbakov, A.M.; Kalinovskiy, V.P.; Novik, V.I.; Chepik, O.F.; Aleksandrov, V.A.; Sobenin, A.; Orekhov, A.N. Study of the antioxidant drug "Karinat" in patients with chronic atrophic gastritis. Vopr. Onkol., 2004, 50(1), 81-85.
95. Tu, H.K.; Pan, K.F.; Zhang, Y.; Li, W.Q.; Zhang, L.; Ma, J.L.; Li, J.Y.; You, W.C. Manganese superoxide dismutase polymorphism and risk of gastric lesions, and its effects on chemoprevention in a Chinese population.Cancer Epidemiol. Biomarkers Prev., 2010, 19(4), 1089-1097.
96. Kim, I.W.; Bae, S.M.; Kim, Y.W.; Liu, H.B.; Bae, S.H.; Choi, J.Y.; Yoon, S.K.; Chaturvedi, P.K.; Battogtokh, G.; Ahn, W.S. Serum selenium levels in Korean hepatoma patients. Biol. Trace Elem. Res., 2012, 148(1), 25-31.
97. Yu, S.Y.; Zhu, Y.J.; Li, W.G. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol. Trace Elem. Res., 1997, 56(1), 117-124.
98. Yu, S.Y.; Li, W.G.; Zhu, Y.J.; Yu, W.P.; Hou, C. Chemoprevention trial of human hepatitis with selenium supplementation in China. Biol. Trace Elem. Res., 1989, 20(1-2), 15-22.
99. Tsuji, S.; Tsujii, M.; Murata, H.; Nishida, T.; Komori, M.; Yasumaru, M.; Ishii, S.; Sasayama, Y.; Kawano, S.; Hayashi, N. Helicobacter pylori eradication to prevent gastric cancer: underlying molecular and cellular mechanisms.World J. Gastroenterol., 2006, 12(11), 1671-1680.
100. [100][100] Lee, S.Y.; Shin, Y.W.; Hahm, K.B. Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection. J. Dig. Dis., 2008, 9(3), 129-139.
101. [101][101] Goodman, M.T.; Kiviat, N.; McDuffie, K.; Hankin, J.H.; Hernandez, B.; Wilkens, L.R.; Franke, A.; Kuypers, J.; Kolonel, L.N.; Nakamura, J.; Ing, G.; Branch, B.; Bertram, C.C.; Camelot, L.; Sharma, S.; Killeen, J. The association of plasma micronutrients with the risk of cervical dysplasia inHawaii.Cancer Epidemiol. Biomarkers Prev., 1998, 7(6), 537-544.
102. [102][102] Tomita, L.Y.; Longatto, F. A.; Costa, M.C.; Andreoli, M.A.; Villa, L.L.; Franco, E.L.; Cardoso, M.A. Diet and serum micronutrients in relation to cervical neoplasia and cancer among low-income Brazilian women. Int. J. Cancer, 2010, 126(3), 703-714.
103. [103][103] Atlante, M.; Mariani, L.; Luci, M.; Carico, E.; Diotallevi, F.; Iacovelli, A.; Vincenzoni, C. The role of some micronutrients in the evolution of HPV infection. Minerva Ginecol., 2002, 54(2), 179-183.
104. [104][104] Stockfleth, E.; Beti, H.; Orasan, R.; Grigorian, F.; Mescheder, A.; Tawfik, H.; Thielert, C. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br. J. Dermatol., 2008, 158(6), 1329-1338.
105. [105][105] Garcia, F.A.; Cornelison, T.; Nuno, T.; Greenspan, D.L.; Byron, J.W.; Hsu, C.H.; Alberts, D.S.; Chow, H.H. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia. Gynecol. Oncol., 2014, 132(2), 377-382.
106. [106][106] Shukla, S.; Bharti, A.C.; Hussain, S.; Mahata, S.; Hedau, S.; Kailash, U.; Kashyap, V.; Bhambhani, S.; Roy, M.; Batra, S.; Talwar, G.P.; Das, B.C. Elimination of high-risk human papillomavirus type HPV16 infection by ‘Praneem’ polyherbal tablet in women with early cervical intraepithelial lesions. J. Cancer Res. Clin. Oncol., 2009, 135(12), 1701-1709.
107. [107][107] Palan, P.R.; Chang, C.J.; Mikhail, M.S.; Ho, G.Y.; Basu, J.; Romney, S.L. Plasma concentrations of micronutrients during a ninemonth clinical trial of beta-carotene in women with precursor cervical cancer lesions. Nutr. Cancer, 1998, 30(1), 46-52.
108. [108][108] Talwar, G.P.; Dar, S.A.; Rai, M.K.; Reddy, K.V.; Mitra, D.; Kulkarni, S.V.; Doncel, G.F.; Buck, C.B.; Schiller, J.T.; Muralidhar, S.; Bala, M.; Agrawal, S.S.; Bansal, K.; Verma, J.K. A novel polyherbal microbicide with inhibitory effect on bacterial, fungal and viral genital pathogens. Int. J. Antimicrob. Agents, 2008, 32(2), 180-185.
109. [109][109] Basu, P.; Dutta, S.; Begum, R.; Mittal, S.; Dutta, P.D.; Bharti, A.C.; Panda, C.K.; Biswas, J.; Dey, B.; Talwar, G.P.; Das, B.C. Clearance of cervical human papillomavirus infection by topical application of curcumin and curcumin containing polyherbal cream: a phase II randomized controlled study. Asian Pac. J. Cancer Prev., 2013, 14(10), 5753-5759.
110. [110][110] Bjelakovic, G.; Nikolova, D.; Simonetti, R.G.; Gluud, C. Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements. Aliment. Pharmacol. Ther., 2008, 28(6), 689-703.
111. [111][111] D’Incalci, M.; Steward, W.P.; Gescher, A.J. Modulation of response to cancer chemotherapeutic agents by diet constituents: is the available evidence sufficiently robust for rational advice for patients? Cancer Treat. Rev., 2007, 33(3), 223-229.
112. [112][112] Groenbaek, K.; Friis, H.; Hansen, M.; Ring-Larsen, H.; Krarup, H.B. The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients. Eur. J. Gastroenterol. Hepatol., 2006, 18(9), 985-989.
113. [113] Philipson, T.J.; Thornton Snider, J.; Lakdawalla, D.N.; Benoit Stryckman, MA; Goldman, D.R. Impact of oral nutritional supplementation on hospital outcomes. Am. J. Managed Care, 2013, 19(2) ,121-128.
114. [114][114] Bengmark, S. Integrative medicine and human health-the role of pre-, pro-and synbiotics. Clin. Transl. Med., 2012, 1(1), 6. doi: 10.1186/2001-1326-1-6.
115. [115][115] Muecke, R.; Schomburg, L.; Buentzel, J.; Kisters, K.; Micke, O. Selenium or no selenium--that is the question in tumor patients: a new controversy. Integr. Cancer Ther., 2010, 9(2), 136-141.
116. [116][116] Kangwan, N.; Park, J.M.; Kim, E.H.; Hahm, K.B. Quality of healing of gastric ulcers: Natural products beyond acid suppression. Quality of healing of gastric ulcers: Natural products beyond acid suppression. World J. Gastrointest. Pathophysiol., 2014, 5(1), 40-47.
117. [117][117] Vargas, A.J.; Burd, R. Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr. Rev., 2010, 68(7), 418-428.
118. [118][118] Par, A.; Roth, E.; Miseta, A.; Hegedus, G.; Par, G.; Hunyady, B.; Vincze, A. Effects of supplementation with the antioxidant flavonoid, silymarin, in chronic hepatitis C patients treated with peginterferon + ribavirin. A placebo-controlled double blind study. Orv. Hetil., 2009, 150(2), 73-79.
119. [119][119] Kou, X.; Kirberger, M.; Yi Yang, Y.; Chen, N. Natural products for cancer prevention associated with Nrf2-ARE pathway. Food Sci. Human Wellness, 2013, 2(1), 22-28.
120. [120][120] Murakami, A.; Ohigashi, H. Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int. J. Cancer, 2007, 121(11), 2357-2363.
121. [121][121] Singh, M.; Tyagi, S.; Bhui, K.; Prasad, S.; Shukla, Y. Regulation of cell growth through cell cycle arrest and apoptosis in HPV 16 positive human cervical cancer cells by tea polyphenols. Invest. New Drugs, 2010, 28(3), 216-224.
122. [122][122] Akai, Y.; Nakajima, N.; Ito, Y.; Matsui, T.; Iwasaki, A.; Arakawa, Y. Green Tea Polyphenols Reduce Gastric Epithelial Cell Proliferation and Apoptosis Stimulated by Helicobacter pylori Infection. J. Clin. Biochem. Nutr., 2007, 40(2), 108-115.
123. [123][123] Pasechnikov, V.; Chukov, S.; Fedorov, E.; Kikuste, I.; Leja, M. Gastric cancer: Prevention, screening and early diagnosis. World J. Gastroenterol., 2014, 20(38), 13842-13862.
124. [124][124] Romero, C.; Medina, E.; Vargas, J.; Brenes, M.; De Castro, A. In vitro activity of olive oil polyphenols against Helicobacter pylori. J. Agric. Food Chem., 2007, 55(3), 680-686.
125. [125][125] Niehues, M.; Stark, T.; Keller, D.; Hofmann, T.; Hensel, A. Antiadhesion as a functional concept for prevention of pathogens: N-Phenylpropenoyl-L-amino acid amides as inhibitors of the Helicobacter pylori BabA outer membrane protein. Mol. Nutr. Food Res., 2011, 55(7), 1104-1117.
126. [126][126] Zaidi, S.F.; Yamamoto, T.; Refaat, A.; Ahmed, K.; Sakurai, H.; Saiki, I.; Kondo, T.; Usmanghani, K.; Kadowaki, M.; Sugiyama, T. Modulation of activation-induced cytidine deaminase by curcumin in Helicobacter pylori-infected gastric epithelial cells. Helicobacter., 2009, 14(6), 588-595.
127. [127][127] Zaidi, S.F.; Ahmed, K.; Yamamoto, T.; Kondo, T.; Usmanghani, K.; Kadowaki, M.; Sugiyama, T. Effect of resveratrol on Helicobacter pylori-induced interleukin-8 secretion, reactive oxygen species generation and morphological changes in human gastric epithelial cells. Biol. Pharm. Bull., 2009, 32(11), 1931-1935.
128. [128][128] Lin, H.C.; Chen, Y.F.; Hsu, W.H.; Yang, C.W.; Kao, C.H.; Tsai, T.F. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev. Res. (Phila), 2012, 5(7), 952-962.
129. [129][129] Patel, K.R.; Scott, E.; Brown, V.A.; Gescher, A.J.; Steward, W.P.; Brown, K. Clinical trials of resveratrol. Ann.N. Y. Acad. Sci., 2013, 1215, 161-169.
130. [130][130] Subramanian, L.; Youssef, S.; Bhattacharya, S.; Kenealey, J.; Polans, A.S.; van Ginkel, P.R. Resveratrol: challenges in translation to the clinic—a critical discussion. Clin. Cancer Res., 2010, 16(24), 5942-5948.
131. [131][131] Hu, Y.; Wang, S.; Wu, X.; Zhang, J.; Chen, R.; Chen, M.; Wang, Y. Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma. J. Ethnopharmacol., 2013, 149 (3), 601-612.
132. [132][132] Ho, S.S.; Go, M.L. Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity. Bioorg Med. Chem. Lett., 2013, 23(22), 6127-6133.
133. [133][133] Toyoda, T.; Tsukamoto, T.; Mizoshita, T.; Nishibe, S.; Deyama, T.; Takenaka, Y.; Hirano, N.; Tanaka, H.; Takasu, S.; Ban, H.; Kumagai, T.; Inada, K.; Utsunomiya, H.; Tatematsu, M. Inhibitory effect of nordihydroguaiaretic acid, a plant lignan, on Helicobacter pyloriassociated gastric carcinogenesis in Mongolian gerbils. Cancer Sci., 2007, 98(11), 1689-1695.
134. [134][134] Khanna, N.; Dalby, R.; Tan, M.; Arnold, S.; Stern, J.; Frazer, N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol. Oncol., 2007, 107(3), 554-562.
135. [135][135] Greco, N.; Kivi, K.; Qian, S.K.; Leivonen, P.; Auvinen, E. Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One, 2011, 6, e21646. doi: 10.1371/journal.pone.0021646.
136. [136][136] Cherry, J.J.; Rietz, A.; Malinkevich, A.; Liu, Y.; Xie, M.; Bartolowits, M.; Davisson, V.J.; Baleja, J.D.; Androphy, E.J. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function. PLoS One, 2013, 8(12), e84506. doi: 10.1371/journal.pone.0084506.
137. [137][137] Every, A.L.; Stent, A.; Moloney, M.B.; Ng, G.Z.; Skene, C.D. Edwards, S.J.; Sutton, P. Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen. Vaccine, 2011, 29(7), 1514-1518.
138. [138][138] Hwang, Y.J.; Lee, S.P.; Kim, S.Y.; Choi, Y.H.; Kim, M.J.; Lee, C.H.; Lee, J.Y.; Kim, D.Y. Expression of heat shock protein 60 kDa is upregulated in cervical cancer. Yonsei Med. J., 2009, 50(3), 399-406.
139. [139][139] Rochani, A.K.; Singh, M.; Tatu, U. Heat shock protein 90 inhibitors as broad spectrum anti-infectives. Curr. Pharm. Des., 2013, 19(3), 377-386.
140. [140][140] Roman, L.D.; Wilczynski, S.; Muderspach, L.I.; Burnett, A.F.; O'Meara, A.; Brinkman, J.A.; Kast, W.M.; Facio, G.; Felix, J.C.; Aldana, M.; Weber, J.S. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol. Oncol., 2007, 106(3), 558-566.
141. [141][141] Farzanehpour, M.; Soleimanjahi, H.; Hassan, Z.M.; Amanzadeh, A.; Ghaemi, A.; Fazeli, M. HSP70 modified response against HPV based tumor. Eur. Rev. Med. Pharmacol. Sci., 2013, 17(2), 228-234.
142. [142][142] Morris, S.M. Recent advances in arginine metabolism: roles and regulation of the arginases. Br. J. Pharmacol., 2009, 157(6), 922-930.
143. [143][143] Murakami, A. Chemoprevention with phytochemicals targeting inducible nitric oxide synthase. Forum Nutr., 2009, 61, 193-203. doi: 10.1159/000212751.
144. [144][144] Chaturvedi, R.; de Sablet, T.; Coburn, L.A.; Alain P. Gobert, A.P.; Wilson, K.T. Arginine and polyamines in Helicobacter pyloriinduced immune dysregulation and gastric carcinogenesis. Amino Acids, 2012, 42(2-3), 627-640.
145. [145][145] Lewis, N.D.; Asim, M.; Barry, D.P.; Singh, K.; de Sablet, T.; Boucher, J.L.; Gobert, A.P.; Chaturvedi, R.; Wilson, K.T. Arginase II restricts host defense to Helicobacter pylori by attenuating inducible nitric oxide synthase translation in macrophages. J. Immunol., 2010, 184(5), 2572-2582.
146. [146][146] Ashour, A.E.; Abd-Allah, A.R.; Korashy, H.M.; Attia, S.M.; Alzahrani, A.Z.; Saquib, Q.; Bakheet, S.A.; Abdel-Hamied, H.E.; Jamal, S.; Rishi, A.K. Thymoquinone suppression of the human hepatocellular carcinoma cell growth involves inhibition of IL-8 expression, elevated levels of TRAIL receptors, oxidative stress and apoptosis. Mol. Cell Biochem., 2014, 389(1-2), 85-98.
147. [147][147] Lo, Y.L.; Wang, W. Formonenetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro. Chem. Biol. Interact., 2013, 205(3), 188-197.
148. [148][148] He, F.; Wang, Q.; Zheng, X.L.; Yan, J.Q.; Yang, L.; Sun, H.; Hu, L.N.; Lin, Y.; Wang, X. Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species. Oncol. Rep., 2012, 28(2), 601-605.
149. [149][149] Cho, S.H.; Park, M.H.; Lee, H.P.; Back, M.K., Sung, H.C.; Chang, H.W.; Kim, J.H.; Jeong, H.S.; Han, S.B.; Hong, J.T. (E)-2,4-Bis(phydroxyphenyl)-2-butenal enhanced TRAIL-induced apoptosis in ovarian cancer cells through downregulation of NFkB/STAT3 pathway. Arch. Pharm. Res., 2014, 37(5), 652-661.
150. [150][150] Lirdprapamongkol, K.; Sakurai, H.; Abdelhamed, S.; Yokoyama, S.; Athikomkulchai, S.; Viriyaroj, A.; Awale, S.; Ruchirawat, S.; Svasti, J.; Saiki, I. Chrysin overcomes TRAIL resistance of cancer cells through Mcl-1 downregulation by inhibiting STAT3 phosphorylation. Int. J. Oncol., 2013, 43(1), 329-337.
151. [151][151] Zhang, Z.; Ye, T.; Cai, X.; Yang, J.; Lu, W.; Hu, C.; Wang, Z.; Wang, X.; Cao, P. 5,7-dihydroxyflavone enhances the apoptosisinducing potential of TRAIL in human tumor cells via regulation of apoptosis-related proteins. Evid. Based Complement. Alternat. Med., 2013, 2013, 434709. doi: 10.115/2013/434709.
152. [152][152] Kim, E.Y.; Kim, A.K. Combination effect of equol and TRAIL against human cervical cancer cells. Anticancer Res., 2013, 33(3), 903-912.
153. [153][153] Johnstone, R.W.; Frew, A.J.; Smyth, M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer., 2008, 8(10), 782-798.
154. [154][154] Halim, T.A.; Farooqi, A.A.; Zaman, F. Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes. Cancer Cell Int., 2013, 13(1), 61.
155. [155][155] Lagunas-Martinez, A.; Madrid-Marina, V.; Gargle, P. Modulation of apoptosis by early human papillomavirus proteins in cervical cancer. Biochim. Biophys Acta, 2010, 1805(1), 6-16.
156. [156][156] Tan, S.; de Vries, E.G.; van der Zee, A.G.; de Jong, S. Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr. Cancer Drug Targets, 2012, 12(2), 170-184.
157. [157][157] Hougardy, B.M.; Maduro, J.H.; van der Zee, A.G.; de Groot, D.J.; van den Heuvel, F.A.; de Vries, E.G.; de Jong, S. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int. J. Cancer, 2006, 118(8), 1892-1900.
158. [158][158] Grisendi, G.; Bussolari, R.; Cafarelli, L.; Petak, I.; Rasini, V.; Veronesi, E.; De Santis, G., Spano, C.; Tagliazzucchi, M.; Barti-Juhasz, H.; Scarabelli, L.; Bambi, F.; Frassoldati, A.; Rossi, G.; Casali, C.; Morandi, U.; Horwitz, E.M.; Paolucci, P.; Conte, P.; Dominici, M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res., 2010, 70(9), 3718-3729.
159. [159][159] Wang, H.; Davis, J.S.; Wu, X. Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its anti-tumor activity. Mol. Cancer Ther., 2014, 13(3), 643-650.
160. [160][160] Kim, H.; Jeong, D.; Kang, H.E.; Lee, K.C. Na K. A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-coglycolic acid) (PLGA) microspheres. J. Pharm. Pharmacol, 2013, 65(1), 11-21.
161. [161][161] Mitchell, M.J.; Wayne, E.; Rana, K.; Schaffer, C.B.; King, M.R. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc. Natl. Acad. Sci. U S A, 2014, 111(3), 930-935. doi: 10.1073/pans.
162. [162][162] Loebinger, M.R.; Eddaoudi, A.; Davies, D.; Janes, S.M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res., 2009, 69(10), 4134-4142.
163. [163][163] Zheng, Y.; Chen, H.; Zeng, X.; Liu, Z.; Xiao, X.; Zhu Y, Gu D, Mei L. Surface modification of TPGS-b-(PCL-ran-PGA) nanoparticles with polyethyleneimine as a co-delivery system of TRAIL and endostatin for cervical gene therapy. Nanoscale Res. Lett., 2013, 8:161. doi: 10.1186/1556-276X-8-161.
164. [164][164] Forero-Torres, A.; Infante, J.R.; Waterhouse, D., Wong, L.; Vickers, S.; Arrowsmith, E.; He, A.R.; Hart, L.; Trent, D.; Wade, J.; Jin, X.; Wang, Q.; Austin, T.; Rosen, M.; Beckman, R.; von Roemeling, R.; Greenberg, J.; Saleh, M. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Med., 2013, 2(6), 925-932.
165. [165][165] Holland, P.M. Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev., 2014, 25(2), 185-193.
166. [166][166] Horinaka, M.; Yoshida, T.; Shiraishi, T.; Nakata, S.; Wakada, M.; Nakanishi, R.; Nishino, H.; Sakai, T. The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells. Biochem. Biophys. Res. Commun., 2005, 333(3), 833-838.
167. [167][167] Rushworth, S.A.; Micheau, O. Molecular crosstalk between TRAIL and natural antioxidants in the treatment of cancer. Br. J. Pharmacol., 2009, 157(7), 1186-1188.
168. [168][168] Deeb, D.; Xu, Y.X.; Jiang, H.; Gao, X. Janakiraman N, Chapman RA, Gautam SC.Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Mol. Cancer Ther., 2003, 2(1), 95-103.
169. [169][169] Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 2004, 24(5A), 2783-2840.
170. [170] Ganapathy, S.; Chen, Q.; Singh, K.P.; Shankar, S.; Srivastava, R.K. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One, 2010, 5(12):e15627. doi: 10.1371/journal.pone.0015627.
171. [171][171] D’Archivio, M.; Filesi, C.; Vari, R.; Scazzocchio, B.; Masella R. Bioavailability of the polyphenols: status and controversies. Int. J. Mol. Sci., 2010, 11(4), 1321-1342.
172. [172][172] Korkina, L.G.; Pastore, S.; De Luca, C.; Kostyuk, V.A. Metabolism of plant polyphenols in the skin: beneficial versus deleterious effects. Curr. Drug Metab., 2008, 9(8), 710-729.